The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Device Closure of Patent Foramen Ovale After Stroke
Open accessAbstract
Background The comparative effectiveness of percutaneous closure of patent foramen ovale (PFO) plus medical therapy versus medical therapy alone for cryptogenic stroke is uncertain. Objectives We performed the first pooled analysis of individual participant data from completed randomized trials comparing PFO closure versus medical therapy in patients with cryptogenic stroke. Methods We analyzed data on 2 devices (STARFlex and Amplatzer PFO Occluder) evaluated in 3 trials. The primary composite outcome was stroke, transient ischemic attack (TIA), or death; the secondary outcome was stroke. We used log-rank tests and (unadjusted and covariate-adjusted) Cox regression models to compare device closure versus medical therapy. Results Among 2,303 patients, closure was not significantly associated with the primary composite outcome. The difference became significant after covariate adjustment (hazard ratio [HR]: 0.68; p = 0.049). For the outcome of stroke, all comparisons were statistically significant, with unadjusted and adjusted HRs of 0.58 (p = 0.043) and 0.58 (p = 0.044), respectively. In analyses limited to the 2 occluder device trials, the effect of closure was not significant for the composite outcome, but was for the stroke outcome (unadjusted HR: 0.39; p = 0.013. Subgroup analyses did not identify significant heterogeneity of treatment effects. Atrial fibrillation was more common among closure patients. Conclusions Among patients with PFO and cryptogenic stroke, closure reduced recurrent stroke and had a statistically significant effect on the composite of stroke, TIA, and death in adjusted but not unadjusted analyses.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kernan, W. N., Ovbiagele, B., Black, H. R., Bravata, D. M., Chimowitz, M. I., Ezekowitz, M. D., Fang, M. C., Fisher, M., Furie, K. L., Heck, D. V., et al. (2014) · Stroke · doi:10.1161/str.0000000000000024 · Cited by 5,170 · cited 1×
“Current AHA/ASA guidelines do not support the use of PFO closure among patients with PFO and cryptogenic stroke (21).”
BackgroundSacco, R. L., Kasner, S. E., Broderick, J. P., Caplan, L. R., Connors, J. J. (., Culebras, A., Elkind, M. S. V., George, M. G., Hamdan, A. D., Higashida, R. T., et al. (2013) · Stroke · doi:10.1161/str.0b013e318296aeca · Cited by 3,569
Meta-analysis of individual participant data: rationale, conduct, and reporting
Riley, R. D., Lambert, P. C., & Abo-Zaid, G. (2010) · BMJ · doi:10.1136/bmj.c221 · Cited by 1,701 · cited 1×
“received September 29, 2015; revised manuscript received Nove results extracted from trial publications (9), including the ability to standardize outcome definitions and analyses across studies without any reliance on numerical approximations, which are often necessary when extracting data from publications.”
BackgroundCumulative Meta-Analysis of Therapeutic Trials for Myocardial Infarction
Lau, J., Antman, E. M., Jimenez-Silva, J., Kupelnick, B., Mosteller, F., & Chalmers, T. C. (1992) · New England Journal of Medicine · doi:10.1056/nejm199207233270406 · Cited by 1,140 · cited 1×
“In such circumstances, evidence synthesis across trials is appropriate and provides more powerful tests and more precise estimates of the treatment effect than separate analyses of the individual trials (22).”
BackgroundHernández, A. V., Eijkemans, M. J. C., & Steyerberg, E. W. (2006) · Annals of Epidemiology · doi:10.1016/j.annepidem.2005.09.007 · Cited by 65
Cited by
Kleindorfer, D. O., Towfighi, A., Chaturvedi, S., Cockroft, K. M., Gutierrez, J., Lombardi-Hill, D., Kamel, H., Kernan, W. N., Kittner, S. J., Leira, E. C., et al. (2021) · Stroke · doi:10.1161/str.0000000000000375 · Cited by 3,237
Hankey, G. J. (2017) · The Lancet · doi:10.1016/s0140-6736(16)30962-x · Cited by 1,226
Patent Foramen Ovale Closure or Anticoagulation vs. Antiplatelets after Stroke
Mas, J.-L., Derumeaux, G., Guillon, B., Massardier, E., Hosseini, H., Mechtouff, L., Arquizan, C., Béjot, Y., Vuillier, F., Detante, O., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1705915 · Cited by 1,183
Patent Foramen Ovale Closure or Antiplatelet Therapy for Cryptogenic Stroke
Søndergaard, L., Kasner, S. E., Rhodes, J. F., Andersen, G., Iversen, H. K., Nielsen-Kudsk, J. E., Settergren, M., Sjöstrand, C., Roine, R. O., Hildick-Smith, D., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707404 · Cited by 1,137
Long-Term Outcomes of Patent Foramen Ovale Closure or Medical Therapy after Stroke
Saver, J. L., Carroll, J. D., Thaler, D. E., Smalling, R. W., MacDonald, L. A., Marks, D. S., & Tirschwell, D. L. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1610057 · Cited by 1,127
Self-citation
Metadata
- Authors
- Kent, D. M., Dahabreh, I. J., Ruthazer, R., Furlan, A. J., Reisman, M., Carroll, J. D., Saver, J. L., Smalling, R. W., Jüni, P., Mattle, H. P., Meier, B., & Thaler, D. E.
- Venue
- Journal of the American College of Cardiology
- Publisher
- Elsevier BV
- Published
- 2016-03
- Volume
- 67
- Issue
- 8
- Pages
- 907-917
- ISSN
- 0735-1097 (ISSN-L)
- OpenAlex
- W2274435192
- Cited by
- 207
- References
- 5
- FWCI
- 37.87
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.